<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355196</url>
  </required_header>
  <id_info>
    <org_study_id>CLRX712X2101</org_study_id>
    <nct_id>NCT03355196</nct_id>
  </id_info>
  <brief_title>First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients</brief_title>
  <official_title>A Randomized, Placebo Controlled, Subject and Investigator Blinded, first-in- Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics After Intra-articular Injection of LRX712 Into the Knee of Osteoarthritic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate, for the first time in humans, safety and tolerability of&#xD;
      single ascending doses of intra-articular (i.a.) injections of LRX712 into the knee of&#xD;
      patients with moderate osteoarthritis (OA), in order to support the further clinical&#xD;
      development. This study will also allow establishment of the systemic and local&#xD;
      pharmacokinetics (PK) of LRX712 and the exploration of biomarkers of cartilage breakdown and&#xD;
      regeneration in OA patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single intra-articular (i.a.) injection in Osteoarthritic (OA) patients</measure>
    <time_frame>Day 29</time_frame>
    <description>To evaluate Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single i.a. injection in osteoarthritic patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Time to Reach the Maximum Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Area under the plasma concentration-time curve from time zero to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F - Total clearance</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - CL/F - Total clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F - Volume of Distribution</measure>
    <time_frame>pre-dose to 29 days post-dose</time_frame>
    <description>To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Vz/F - Volume of Distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Patients With Moderate Knee Osteoarthritis (30 - 65 Years)</condition>
  <arm_group>
    <arm_group_label>LRX712</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LRX712 given intra-articularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given intra-articularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LRX712</intervention_name>
    <description>Ascending single dose on Day 1</description>
    <arm_group_label>LRX712</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ascending single dose on Day 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients, 30 to 65 years of age inclusive, and in good health as&#xD;
             determined by medical history, physical examination, vital signs, electrocardiogram,&#xD;
             and laboratory tests at screening.&#xD;
&#xD;
          -  At screening, and at baseline vital signs (systolic and diastolic blood pressure and&#xD;
             pulse rate) will be assessed in the sitting position after the subject has rested for&#xD;
             at least three minutes, and again (when required) after three minutes in the standing&#xD;
             position as outlined in the SOM.&#xD;
&#xD;
        Sitting vital signs should be guided by the following ranges:&#xD;
&#xD;
          -  body temperature between 35.0-37.5 °C&#xD;
&#xD;
          -  systolic blood pressure 90-139 mm Hg&#xD;
&#xD;
          -  diastolic blood pressure 50-89 mm Hg&#xD;
&#xD;
          -  pulse rate, 40 - 90 bpm • Subjects must weigh at least 50 kg to participate in the&#xD;
             study, and must have a body mass index (BMI) within the range of 18 - 32 kg/m2. BMI =&#xD;
             Body weight (kg) / [Height (m)]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of enrollment, or within 30 days, whichever is longer; or longer if required by local&#xD;
             regulations&#xD;
&#xD;
          -  A history of clinically significant ECG abnormalities, or any of the following ECG&#xD;
             abnormalities at screening and baseline&#xD;
&#xD;
               -  PR &gt; 200 msec&#xD;
&#xD;
               -  QRS complex &gt; 120 msec&#xD;
&#xD;
               -  QTcF &gt; 450 msec (males)&#xD;
&#xD;
               -  QTcF &gt; 460 msec (females)&#xD;
&#xD;
          -  Known family history or known presence of long QT syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17606</url>
    <description>Results for CLRX712X2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=381</url>
    <description>A Plain Language Trial Summary is available on novartisclinicatrials.com</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritic patients</keyword>
  <keyword>Cartilage</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

